|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DOLK |
Gene summary for DOLK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DOLK | Gene ID | 22845 |
| Gene name | dolichol kinase | |
| Gene Alias | CDG1M | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A0S2Z597 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22845 | DOLK | C04 | Human | Oral cavity | OSCC | 2.29e-02 | 2.83e-01 | 0.2633 |
| 22845 | DOLK | C21 | Human | Oral cavity | OSCC | 3.00e-21 | 6.16e-01 | 0.2678 |
| 22845 | DOLK | C30 | Human | Oral cavity | OSCC | 4.77e-34 | 1.33e+00 | 0.3055 |
| 22845 | DOLK | C38 | Human | Oral cavity | OSCC | 6.85e-08 | 6.84e-01 | 0.172 |
| 22845 | DOLK | C43 | Human | Oral cavity | OSCC | 1.07e-05 | 1.19e-01 | 0.1704 |
| 22845 | DOLK | C46 | Human | Oral cavity | OSCC | 5.67e-05 | 2.23e-01 | 0.1673 |
| 22845 | DOLK | C57 | Human | Oral cavity | OSCC | 4.60e-02 | 1.56e-01 | 0.1679 |
| 22845 | DOLK | C06 | Human | Oral cavity | OSCC | 7.80e-05 | 6.57e-01 | 0.2699 |
| 22845 | DOLK | C08 | Human | Oral cavity | OSCC | 1.32e-08 | 1.98e-01 | 0.1919 |
| 22845 | DOLK | SYSMH1 | Human | Oral cavity | OSCC | 1.23e-07 | 1.94e-01 | 0.1127 |
| 22845 | DOLK | SYSMH2 | Human | Oral cavity | OSCC | 2.33e-06 | 1.68e-01 | 0.2326 |
| 22845 | DOLK | SYSMH3 | Human | Oral cavity | OSCC | 6.04e-11 | 2.42e-01 | 0.2442 |
| 22845 | DOLK | SYSMH6 | Human | Oral cavity | OSCC | 2.69e-06 | 8.30e-02 | 0.1275 |
| 22845 | DOLK | P1_cSCC | Human | Skin | cSCC | 1.56e-08 | 2.91e-01 | 0.0292 |
| 22845 | DOLK | P2_cSCC | Human | Skin | cSCC | 5.59e-06 | 2.36e-01 | -0.024 |
| 22845 | DOLK | P4_cSCC | Human | Skin | cSCC | 8.37e-04 | 1.72e-01 | -0.00290000000000005 |
| 22845 | DOLK | P10_cSCC | Human | Skin | cSCC | 2.95e-08 | 2.55e-01 | 0.1017 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
| GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
| GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:0006490 | Oral cavity | OSCC | oligosaccharide-lipid intermediate biosynthetic process | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
| GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
| GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
| GO:00064877 | Skin | cSCC | protein N-linked glycosylation | 33/4864 | 65/18723 | 1.63e-05 | 1.99e-04 | 33 |
| GO:00064883 | Skin | cSCC | dolichol-linked oligosaccharide biosynthetic process | 10/4864 | 18/18723 | 7.25e-03 | 3.44e-02 | 10 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DOLK | SNV | Missense_Mutation | c.1284N>T | p.Gln428His | p.Q428H | Q9UPQ8 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DOLK | SNV | Missense_Mutation | novel | c.962N>G | p.Lys321Arg | p.K321R | Q9UPQ8 | protein_coding | tolerated(0.23) | benign(0.033) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DOLK | SNV | Missense_Mutation | rs373115419 | c.8G>A | p.Arg3Gln | p.R3Q | Q9UPQ8 | protein_coding | tolerated_low_confidence(0.16) | benign(0.003) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| DOLK | insertion | Frame_Shift_Ins | novel | c.329_330insGAGGCACTGC | p.Phe110LeufsTer87 | p.F110Lfs*87 | Q9UPQ8 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| DOLK | insertion | Nonsense_Mutation | novel | c.597_598insAGTTTGTGAGTGAGCAGGGACCTTGGAATA | p.Gly199_Gly200insSerLeuTerValSerArgAspLeuGlyIle | p.G199_G200insSL*VSRDLGI | Q9UPQ8 | protein_coding | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| DOLK | SNV | Missense_Mutation | c.1057A>G | p.Ile353Val | p.I353V | Q9UPQ8 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| DOLK | SNV | Missense_Mutation | novel | c.1181N>A | p.Leu394His | p.L394H | Q9UPQ8 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| DOLK | SNV | Missense_Mutation | c.1114T>G | p.Phe372Val | p.F372V | Q9UPQ8 | protein_coding | tolerated(0.56) | benign(0.027) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DOLK | SNV | Missense_Mutation | c.560N>A | p.Arg187His | p.R187H | Q9UPQ8 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DOLK | SNV | Missense_Mutation | novel | c.871C>A | p.Leu291Ile | p.L291I | Q9UPQ8 | protein_coding | tolerated(0.23) | benign(0.069) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |